Seagen
E854988
Seagen is a biotechnology company specializing in the development of antibody-drug conjugate (ADC) therapies for cancer treatment.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Seagen canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T10292258 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Seagen Context triple: [Genmab, collaboratesWith, Seagen]
-
A.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
B.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
C.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
D.
Keytruda
Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.
-
E.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Seagen Target entity description: Seagen is a biotechnology company specializing in the development of antibody-drug conjugate (ADC) therapies for cancer treatment.
-
A.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
B.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
C.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
D.
Keytruda
Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.
-
E.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
biotechnology company
ⓘ
public company ⓘ |
| acquiredBy | Pfizer ⓘ |
| acquisitionAnnounced | 2022 ⓘ |
| acquisitionValueUSD | 43000000000 ⓘ |
| AdcetrisIndication |
Hodgkin lymphoma
ⓘ
systemic anaplastic large cell lymphoma ⓘ |
| collaboratesWith |
Astellas Pharma
ⓘ
linked to:
Astellas
Genmab ⓘ Merck & Co. ⓘ Takeda Pharmaceutical Company ⓘ |
| coreModality |
cytotoxic payloads
ⓘ
linker technologies ⓘ monoclonal antibodies ⓘ |
| country |
United States
ⓘ
linked to:
United States of America
|
| developed |
Adcetris
ⓘ
linked to:
brentuximab vedotin
enfortumab vedotin ⓘ |
| focusesOn |
cancer treatment
ⓘ
targeted cancer therapies ⓘ |
| formerName | Seattle Genetics ⓘ |
| foundedBy |
Clay Siegall
ⓘ
H. Perry Fell ⓘ |
| hasEmployeeType |
clinical researchers
ⓘ
scientists ⓘ |
| hasProduct |
Adcetris
ⓘ
Padcev ⓘ Tukysa ⓘ |
| hasTechnology | antibody-drug conjugate platform ⓘ |
| hasTherapy |
brentuximab vedotin
ⓘ
enfortumab vedotin ⓘ tisotumab vedotin ⓘ tucatinib ⓘ |
| headquartersLocation |
Bothell, Washington
ⓘ
linked to:
Bothell
|
| inception | 1997 ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| locatedIn |
Washington (state)
ⓘ
linked to:
Washington
|
| PadcevIndication | urothelial carcinoma ⓘ |
| regulatoryRegion | FDA-approved products ⓘ |
| researchArea |
hematologic malignancies
ⓘ
solid tumors ⓘ |
| specializesIn |
antibody-drug conjugates
ⓘ
oncology therapeutics ⓘ |
| tickerSymbol | SGEN ⓘ |
| tisotumabVedotinIndication | recurrent or metastatic cervical cancer ⓘ |
| tradedOn | NASDAQ ⓘ |
| TukysaIndication | HER2-positive breast cancer ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Seagen Description of subject: Seagen is a biotechnology company specializing in the development of antibody-drug conjugate (ADC) therapies for cancer treatment.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject linked to:
GMAB